Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| INO | 424B5 | bearish | 6/10 | Inovio Pharmaceuticals (INO) is raising ~$18.3M net via a 424B5 takedown from its $300M shelf, selling 21.1M shares and | Jul 30, 2026 |
| MYGN | PRESS-RELEASE | bearish | 7/10 | Myriad Genetics reported Q2 2026 revenue of $190.7M (11% YoY decline, 7.4% below consensus) and adjusted EPS of -$0.25 ( | Jul 30, 2026 |
| SXTP | PRESS-RELEASE | bearish | 6/10 | Sixty Degrees Pharmaceuticals announced a private placement of 574,713 shares (or pre-funded warrants) with Series A and | Jul 30, 2026 |
| AMRX | DEFA14A | neutral | 5/10 | Amneal Pharmaceuticals filed a DEFA14A on July 30, 2026, providing additional proxy soliciting materials related to the | Jul 30, 2026 |
| PHAT | 8-K | mixed | 5/10 | Phathom Pharmaceuticals reported Q2 2026 net revenue of $74.3M (up 88% YoY, beating consensus of $72.7M) and non-GAAP ad | Jul 30, 2026 |
| GSK | 6-K | neutral | 2/10 | GSK filed a routine 6-K disclosing that President of Global Supply Chain Regis Simard sold 38,000 ordinary shares at £20 | Jul 30, 2026 |
| MDGL | 8-K | bullish | 7/10 | Madrigal Pharmaceuticals reported Q2 2026 Rezdiffra net sales of $364.3M, up 71% YoY, beating consensus revenue estimate | Jul 30, 2026 |
| BMY | 8-K | bullish | 7/10 | Bristol Myers Squibb reported Q2 2026 results significantly above consensus, with non-GAAP EPS of $2.04 beating the $1.6 | Jul 30, 2026 |
| BCYC | 8-K | neutral | 5/10 | Bicycle Therapeutics reported Q2 2026 financial results with a net loss of $50.3M ($-0.72/share), narrowing from a $79.0 | Jul 30, 2026 |
| HCM | 6-K | bullish | 6/10 | HUTCHMED reported H1 2026 results with total revenue essentially flat at $278.3M (vs $277.7M in H1 2025) but a strong 23 | Jul 30, 2026 |
| TVRD | 8-K | bullish | 6/10 | Tvardi Therapeutics announced the selection of ulcerative colitis (UC) as the initial indication for TTI-109, its next-g | Jul 30, 2026 |
| SNY | 6-K | mixed | 6/10 | Sanofi reported H1 2026 net sales of €22,106M (+11.1% reported, +15.7% CER), driven by Dupixent (+34.4% CER) and new lau | Jul 30, 2026 |
| CBIO | 8-K | neutral | 3/10 | Crescent Biopharma reported Q2 2026 financial results with net loss of $24.8M ($0.74 per share) vs $21.8M in Q2 2025. Th | Jul 30, 2026 |
| EVMN | 8-K | neutral | 5/10 | Evommune announced initiation of a Phase 2b clinical trial for EVO756, an oral MRGPRX2 antagonist, for migraine prophyla | Jul 30, 2026 |
| ENLV | 6-K | bullish | 5/10 | Enlivex reported that Rain protocol trading volume reached $860M as of July 29, 2026, representing 622% month-over-month | Jul 30, 2026 |
| LEXX | 8-K | neutral | 4/10 | Lexaria Bioscience Corp. filed an 8-K announcing a 1-for-15 reverse stock split effective August 3, 2026, to regain comp | Jul 30, 2026 |
| MTNB | 425 | bearish | 6/10 | Matinas BioPharma (MTNB) filed this 425 to announce that GH Power, its reverse-merger partner, is continuing preliminary | Jul 30, 2026 |
| VCEL | 8-K | bullish | 6/10 | Vericel reported Q2 2026 revenue of $77.5M (+22% YoY), beating consensus of $72.7M, and GAAP EPS of $0.04 vs -$0.01 a ye | Jul 30, 2026 |
| REPL | 8-K | bullish | 7/10 | Replimune presented its BLA resubmission for RP1 (vusolimogene oderparepvec, TUDRIQEV) in combination with nivolumab to | Jul 30, 2026 |
| MESO | 6-K | bullish | 6/10 | Mesoblast reported Ryoncil net revenue of US$36M for Q4 FY2026 and US$115M for the first full year post-FDA approval, wi | Jul 30, 2026 |
| GRFS | 6-K | neutral | 2/10 | Grifols announced the resignation of independent director Iñigo Sánchez-Asiaín Mardones (Audit Committee Chair, Strategy | Jul 30, 2026 |
| ICLR | 6-K | bearish | 7/10 | ICON plc reported Q2 2026 results with revenue essentially flat (+1.2% to $2.06B) but net income collapsed 64% to $72.6M | Jul 30, 2026 |
| CAPR | PRESS-RELEASE | bearish | 7/10 | The FDA's Cellular, Tissue and Gene Therapies Advisory Committee voted 9-3 against evidence supporting Deramiocel's effe | Jul 30, 2026 |
| IRON | PRESS-RELEASE | bullish | 7/10 | Disc Medicine reported Q2 2026 net loss of $59.5M ($1.54/share), beating consensus of -$1.77 by 13%. The key catalyst is | Jul 30, 2026 |
| NEOG | 8-K | mixed | 6/10 | Neogen reported Q4 FY2026 adjusted EPS of $0.09, sharply beating the $0.03 consensus, but revenue was essentially flat a | Jul 30, 2026 |
| ALNY | 8-K | bearish | 7/10 | Alnylam reported Q2 2026 non-GAAP diluted EPS of $1.84 (missed consensus of $2.15 by 14.5%) and total revenue of $1.291B | Jul 30, 2026 |
| LITS | 8-K | bullish | 6/10 | Lite Strategy announced it repurchased ~4.9 million shares (13% of outstanding) since December 2025 at an average price | Jul 30, 2026 |
| IRON | 8-K | bullish | 7/10 | Disc Medicine reported Q2 2026 net loss of $59.5M ($1.54/share), slightly narrower than the $1.58 consensus. The key new | Jul 30, 2026 |
| AVXL | 8-K | neutral | 3/10 | Anavex reported preliminary Q2 fiscal 2026 results with a net loss of $5.3M ($0.06/share), narrowed from $11.2M ($0.13/s | Jul 30, 2026 |
| REGN | PRESS-RELEASE | bullish | 7/10 | Regeneron reported Q2 2026 non-GAAP EPS of $14.29, a 40.1% beat vs consensus of $10.20, on total revenue of $4.29B (+17% | Jul 30, 2026 |